GANGADHAR MEHER UNIVERSITY AMRUTA VIHAR, SAMBALPUR

No. 3042 / GMU/EC

Pate: 23/04/ 2021

NOTICE ,

All the research scholars of Ph.D. program doing research work on human beings are requested to apply in prescribed format along with the synopsis or related documents for clearance from the institutional Ethics Committee of this University.

The application should reach to the Controller of Examinations on or before 30.04.2021. The application form is available in the University Website i.e. www.gmuniversity.ac.in.

Controller of Examinations

G.M. University, Sambalpur Controller of Examinations

Date: 23 04 202

Memo No. 3043 / GMU / EC

Copy to PA to VC / PA to Registrar / Dy. Registrar / Dean, Rearch / All HoDs with Ph.D. program / System Manager, ICT Cell with a request to upload in University Website for information and necessary action.

Controller of Examinations
G.M. University, Sambalpur

Controller of Examinations G.M. University, Sambalpur

APPLICATION FORM

Institutional Ethics Committee (IEC) for Human Research

1. Name, designation and address of

(To be filled in by the Principal Investigator / Research Scholar for submission to institutional filtes Commission)

Principal Investigator / Research Scholar			
(Attach a curriculum vitae of PI / RS)			
Proposed title of the research work	:		
		/	
3. Brief description of the proposal	:	(Attach separate shee	t with maximum 500 words)
4. Type of study (Tick appropriately)	;	Clinical	Single centre
		Behavioral	Multi centric
		Epidemiological	Others
5. Status of Review	:	New	Revised
Clinical Trials	:		
(i) Does the study involve use of	:	Drug	indian Systems of Medicine/ Alternate System of Medicine
		Devices	Any other
		Vaccines	Not applicable
(ii) Is it approved and marketed	. 1		
(ii) is it approved and marketed	: 1		USA
		UK & Europe	Other countries, specify
(iii) Does it involve a change in use,	:	Yes	No
dosage, route of administration?			
If yes, whether DCGI's/Any other	:	Yes	No
Regulatory authority's permission is obtained?			,,,,
If yes, Date of permission	:		
(iv) Is it an Investigational New Drug?	:	Yes	No
If yes, IND No.:			
(a) Investigator's Brochure submitted	: [Yes	No
(b) In vitro studies data	: [Yes	No
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			
(c) Preclinical Studies done	: [Yes	No
(d) Clinical Study is	: [Phase I	Phase III
	L	Phase II	
	L	riiase II	Phase IV

	(e) Are you aware if this similar study is being elsewhere? If Yes, attach details		[Yes	No	
	ii res, attacii detaks				(.	
Subject boxes)	t selection (Tick the appropr	late	:			
(i)				1		
(11)	Duration of study		:	×.		
(iii)	Will subjects from both se	xes be	: r	Yes	No	
, ,	required		·			
(iv)		- aluan	. 1	Vac	No	
(11)	Inclusion/exclusion criteria	a given	: [Yes	NO	
(v)	Type of subjects		: [Volunteers	Patients	
(vi)	Vulnerable subjects		: [Yes	No	
	•		Ì	Pregnant women	Elderly	
				Fetus	Handicapped	
			-	Terminally ill	Mentally challenged	
				Children	Economically & socially backward	
				Illiterate	Any other	
				Seriously ill		
		140				
(vii)	Special group subjects		:	Yes	No	
	If Yes,			Captive	Nurses/dependent staff	
				Students	Employees	
				Any other	Armed forces	
				Institutionalized		
Conse	nt			[#W/		
Conse			٠	*Written	Oral	
				Audio-visual		
				* If written consent is not obtained give reasons	:	
(i)	Consent form: (Tick the i	ncluded	:	Understandable language	te	
elements)				Statement that study involve research		
				Sponsor of study		
				Purpose and procedures	S	
				Risks & Discomforts		
				Benefits		
				Confidentiality of recor	rds	
				Contact information		
				Statement that consent	t is voluntary	
				Right to withdraw	of higherical material	
				Consent for future use	or biological material	

THE PARTY OF

	9.	Priva	acy and confidentiality	•				
		(i)	Study involves	:	Direct Identifiers			
1/					Indirect Identifiers / co	ded 1.		
/					Completely anonymised	d / delinked		
		(ii)	Confidential handling of data by staff	:	Yes	No		
	10.		any advertising be done for uitment of Subjects?	:	Yes	No		
		(Post	ters, flyers, brochure, websites - if so ly attach a copy)					
	11.	Use o	of biological/hazardous materials	:	· ·			
		(i)	Use of fetal tissue or abortus	:	Yes	No		
		(ii)	Use of organs or body fluids	:	Yes	No		
		(iii)	Use of recombinant/gene therapy		Yes	No		
			If yes, has Department of Biotechnology (DBT) approval for	•	Yes	No		
			rDNA products been obtained?		*	*		
		(iv)	Use of pre-existing/stored/left	:	Yes	No		
			over samples					
		(v)	Collection for banking/future	•	Yes	No		
			research					
		(vi)	Use of ionizing radiation /	:	Yes	No		
			radioisotopes			3		
			If yes, has Bhaba Atomic Research Centre (BARC) approval for Radioactive Isotopes been obtained?	:	Yes	No		
		(vii)	Use of Infectious / bio-hazardous	:	Yes	No		
			specimens If yes, justify with details of collaborators (a) Is the proposal being submitted for clearance from Health Ministry's Screening Committee (HMSC) for International collaborations?					
		(viii)	Proper disposal of material	:	Yes	No		
	12.	Risks	& Benefits	:				
		(i)	Is the risk reasonable compared to the anticipated benefits to subjects		Yes	No		
		(41)	/ community / country?					
		(ii)	Is there physical / social / psychological risk / discomfort?	:	Yes	No		
			If Yes,		Minimal or no risk			
				More than minimum ri	sk			
		(111)	le there a have fit		High risk	7		
		(iii)	Is there a benefit					
			(a) To the subject	:	Direct	Indirect		
			(b) Benefit to society		[Vo.			
			(b) belieffe to society	:	Yes	No		

13.	Data	Monitoring	:			
	(i)	Is there a data & safety monitoring committee / Board? (DSMB)?	:	Yes	No	
	(ii)	Is there a plan for reporting of adverse events?	:	Yes	No	
		If Yes, reporting is done to	:	Sponsor		
				Ethics Committee		_
				DSMB		
						-
	(iii)	Is there a plan for interim analysis of data?		Yes	No	-
	(iv)	Are there plans for storage and	:	Yes	No	
		maintenance of all trial data base? If Yes, for how long				
4.	Is the	ere compensation for participation?	:	Yes	No	I
		If Yes,	:	Monetary	In kind	T
				Specify amount and type:		_
5.	Is the	ere compensation for injury?	:	Yes	No	T
		If Yes,	:	By sponsor	By Investigator	T
				By insurance company	By any other	
6.	Do vo	ou have conflict of interest?		Yes	No	_
				i i i i i i i i i i i i i i i i i i i	,	1
	If Yes, specify:			Financial		T
				Non-financial		

Place: _____

Signature of Applicant

CONSENT FORM

(To be obtained from participants)

_			rch work carried out by
	they has/have already give		all information about his /their research work
			1.3
Му ра	rticipation in the study is	entire	y voluntary.
1.	Name of participant	:	
2.	Address	:	
3.	Telephone No.	:	
4.	Email ID, if any	1:	
			*
Place Date			Signature of the participant
Signa Date	ture & name of witness		Signature & name of the perso obtaining consent Date

INFORMATION SHEET

(To be supplied by Principal Investigator)

1.	Name of the Principal investigator / Research scholar	:	
2.	Address	: /	
3.	Proposed title of the research work	:	. 1
4,	Voluntary participation	:	
5.	Procedure	:	
6.	Duration	:	
7.	Side effects	:	
8.	Risk	:	
9.	Benefits	:	,
0.	Confidentiality		
1.	Sharing the result		
2.	Right to refuse or withdraw	1	
3,	Whom to contact		

Name & desig	nation of Principal Research Scholar
Contact No.	Mesedicii scholar
Email ID	